Gerardus Adrianus Hoogland

Gerardus Adrianus Hoogland

Active Director Director DIN 06673807
DIN 06673807 First appointment Nov 2013 Primary industry Research & Development
Unlock full profile Investments · shareholding · contact details
Current companies 2 active board seats
Past companies 2 historical roles
Total affiliations 4 Since Nov 2013
Shareholding value •••• Premium profile

About Gerardus Adrianus Hoogland

Data last updated:

Gerardus Adrianus Hoogland is a Director at Eyestem Research Private Limited (since 2020) and Director at Cytespace Research Private Limited (since 2013). The companies operate in Research & Development, Pharma and Healthcare. The 2 current companies with reported revenue have a combined latest revenue of ₹3.06 Cr; the largest is Eyestem Research Private Limited at ₹2.13 Cr (FY 2025). Earlier, Gerardus Adrianus Hoogland was a Director at Cytecare Hospitals Private Limited (2015–2025) and Director at Medwell Ventures Private Limited (2015–2023).

DIN 06673807
Primary Designation Director
Industry Research & Development
First Appointment 01 Nov 2013
Oldest Company Age 15 yrs
Largest company Eyestem Research Private Limited · ₹2.13 Cr (FY 2025)
Combined revenue ₹3.06 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Eyestem Research Private Limited U74999KA2015PTC164505
Director07 Sep 20202015₹2.13 Cr (FY 2025)Active
Cytespace Research Private Limited U73100GJ2011PTC064350
Director01 Nov 20132011₹93 Lakh (FY 2025)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Cytecare Hospitals Private Limited U85110GJ2014PTC079078
Director15 Sep 20152014₹93.10 Cr (FY 2024)Active
Medwell Ventures Private Limited U85100DL2014PTC429322
Director15 Jan 20152014₹73.62 Cr (FY 2023)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Cytespace Research Private Limited
Eyestem Research Private Limited
Cytecare Hospitals Private Limited
Medwell Ventures Private Limited
Premium access

Shareholding and investment profile for Gerardus Adrianus Hoogland

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gerardus Adrianus Hoogland

Gerardus Adrianus Hoogland currently holds 2 directorships: Eyestem Research Private Limited (Director, since 07 Sep 2020, revenue ₹2.13 Cr (FY 2025)); Cytespace Research Private Limited (Director, since 01 Nov 2013, revenue ₹93 Lakh (FY 2025)).

Gerardus Adrianus Hoogland was first appointed on 01 Nov 2013 as Director at Cytespace Research Private Limited. The most recent appointment on record is 07 Sep 2020 at Eyestem Research Private Limited.

The 2 current companies of Gerardus Adrianus Hoogland that report revenue have a combined latest revenue of ₹3.06 Cr: Eyestem Research Private Limited ₹2.13 Cr (FY 2025); Cytespace Research Private Limited ₹93 Lakh (FY 2025).

Gerardus Adrianus Hoogland held 2 earlier board appointments: Cytecare Hospitals Private Limited (Director, 15 Sep 2015 to 03 Nov 2025); Medwell Ventures Private Limited (Director, 15 Jan 2015 to 19 Apr 2023).

The current boards of Gerardus Adrianus Hoogland's companies include Ashok Nana Vohra (Eyestem Research Private Limited), Dhruv Sareen (Eyestem Research Private Limited), Jogin Bhairav Desai (Eyestem Research Private Limited), Mahendra Surendra Rao (Eyestem Research Private Limited), Rajani Ravindra Battu (Eyestem Research Private Limited), Ramesh Babu Byrapaneni (Eyestem Research Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available